Latest News on Wockhardt
Showing of 0 - 10 from 39 results
Wockhardt - Total results - 39
May 15, 2019
India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in USThe generic drug makers are named in an anti-trust lawsuit in the US on allegations of engaging in a conspiracy to fix prices
Jan 05, 2017
US FDA issues warning letter to Wockhardt’s Ankleshwar plantUS FDA has already banned import of products from the facility into the US market since 5 August 2016
Jul 14, 2016
Wockhardt looking to raise Rs 1,200 cr via NCDs to repay debtThe company said it will utilise the money to re-pay or pre-pay term loan availed by it and for general corporate purposes
Aug 30, 2015
Sun, Wockhardt recall drugs from US marketBupropion is an antidepressant used to treat major depressive disorder and seasonal affective disorder.
May 29, 2015
Wockhardt hopes to resolve FDA ban on two plants in FY16Wockhardt has been hit by slowing sales in the US ever since the FDA banned exports from the company's Waluj and Chikalthana plants in Maharashtra in 2013, citing production quality lapses.
May 19, 2015
Mid-cap pharma shares buck weak sentiment; Aurobindo, Wockhardt up nearly 3%Recovery in mid-cap pharma shares comes even as the benchmark Sensex and other key indices continue to linger in negative territory
Apr 28, 2015
Wockhardt recalls 12-15 drugs from US market; shares tumble up to 11%The company clarified to CNBC-TV18 that it has taken measures to resolve the FDA's concerns
Feb 20, 2015
Nifty Changes: DLF, JSPL to be replaced by Yes Bank and Idea CellularRealty major DLF and Naveen Jindal-led Jindal Steel & Power will be dropped from the National Stock Exchange's benchmark index Nifty from 27 March.
Feb 04, 2015
Earnings: Wockhardt Q3 profit up 14% to Rs 347.25 crWockhardt Ltd today reported 14.05 percent increase in consolidated net profit at Rs 347.25 crore for the third quarter ended December 31, 2014-15.
Jan 11, 2015
Govt wants its officials present during FDA inspections at pharma unitsPerturbed by Indian drug-makers frequently running into overseas regulatory problems, the government has requested the US health watchdog FDA to allow its officials during inspections of domestic pharma units.